RE:New Press Release - Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meetinghttps://www.cancer.gov/news-events/cancer-currents-blog/2023/oncolytic-virus-blocking-tgf-beta
A major rate-limiting factor with oncolytic virus continues to be the need to inject them directly into tumors, Dr. Gulley said. Injection is relatively easy for cancers in the skin, such as melanoma, he continued, but it's much more difficult for tumors located deeper in the body.
So to expand their use, researchers need to find ways to make oncolytic viruses that are “logistically easier to give to patients,” Dr. Gulley said.
Dr. Delgoffe and his team have licensed their modified oncolytic virus to a biotechnology company for further development into a clinical agent. He said he hopes that alterations to the treatment can be made that allow it to be delivered by infusion into the blood stream so it can get to hard-to-reach tumors.